您的位置：
首页
>
农业专利
>
详情页
Dry powder formulations and methods for treating pulmonary diseases
专利权人:
PULMATRIX INC.
发明人:
LIPP MICHAEL M,SUNG JEAN C
申请号：
NZ62106510
公开号：
NZ621065A
申请日:
2010.03.26
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Disclosed herein are respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection. Examples of salts used herein are divalent salts such as divalent calcium salts (e.g. calcium sulfate) and monovalent salts such as a lithium salt, potassium salt or sodium salt (e.g. sodium chloride).
来源网站：
中国工程科技知识中心
来源网址：
http://www.ckcest.cn/home/
相关专利
use of a compound with ep4 antagonistic activity or a pharmaceutically acceptable salt thereof, use of a compound of formula (i), (ii), (iii), (iv), (va) or (vb) or a pharmaceutically acceptable salt thereof, pharmaceutical composition for treating cartilage disease, method for treating cartilage disease in an animal subject, including a mammalian subject and compound of formula (i), (ii), (iii), (iv), ( va) or (vb) or a pharmaceutically acceptable salt thereof.
EP4 USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE
use of a compound with ep4 antagonistic activity or a pharmaceutically acceptable salt thereof, use of a compound of formula (i), (ii), (iii), (iv), (va) or (vb), or a salt pharmaceutically acceptable drug thereof, pharmaceutical composition and method for treating il-23 mediated diseases in an animal subject, including a mammalian subject
Use of EP4 receptor antagonists to treat cartilage diseases
USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES
